Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rani Therapeutics Holdings (RANI) Operating Expenses (2020 - 2025)

Rani Therapeutics Holdings (RANI) has 6 years of Operating Expenses data on record, last reported at $7.3 million in Q3 2025.

  • For Q3 2025, Operating Expenses fell 38.49% year-over-year to $7.3 million; the TTM value through Sep 2025 reached $45.9 million, down 11.31%, while the annual FY2024 figure was $54.3 million, 17.79% down from the prior year.
  • Operating Expenses reached $7.3 million in Q3 2025 per RANI's latest filing, down from $10.5 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $27.8 million in Q3 2021 and bottomed at $6.0 million in Q1 2021.
  • Average Operating Expenses over 5 years is $14.1 million, with a median of $13.8 million recorded in 2022.
  • Peak YoY movement for Operating Expenses: soared 1229.23% in 2021, then plummeted 41.18% in 2022.
  • A 5-year view of Operating Expenses shows it stood at $13.4 million in 2021, then surged by 30.83% to $17.5 million in 2022, then fell by 23.16% to $13.4 million in 2023, then increased by 19.0% to $16.0 million in 2024, then crashed by 54.6% to $7.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $7.3 million in Q3 2025, $10.5 million in Q2 2025, and $12.2 million in Q1 2025.